

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



COMMON SPLENDOR INTERNATIONAL HEALTH INDUSTRY GROUP LIMITED

(Incorporated in Bermuda with limited liability)

(Stock Code: 286)

VOLUNTARY ANNOUNCEMENT

STRATEGIC COOPERATION FRAMEWORK AGREEMENT WITH ROYAL HERBALIST

This is a voluntary announcement made by Common Splendor International Health Industry Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to provide shareholders of the Company and potential investors on the Group’s latest business development.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces that, on 14 December 2016, the Company entered into the strategic cooperation framework agreement (the “**Framework Agreement**”) with 樂氏同仁藥業科技集團有限公司 (Royal Herbalist Pharmaceutical Technology Group Co., Ltd.*) (“**Royal Herbalist**”, together with the Company, the “**Parties**”) in respect of, among other things, business cooperation between the Parties in the field of Chinese medicine.

THE AIM AND SCOPE OF COOPERATION

The aim of the strategic cooperation between the Parties pursuant to the Framework Agreement includes overall enhancement of the Parties’ business potential, capturing development potential of the Chinese medical industry in the PRC and the brand of 樂氏同仁 (Royal Herbalist*), and thereby expanding the Parties’ market share and creating greater business value through the Parties’ cooperation.

The scope of cooperation includes (a) the creation of sales channels in the PRC for the brand of 樂氏同仁 (Royal Herbalist*) in the field of medicine; (b) the creation of a new business model for the complementing advantages of Chinese medicine, to support Royal Herbalist’s development in the Chinese medicine industry and optimise the Parties’ resources allocation, establishment of business foundation in realising the value of the brand of 樂氏同仁 (Royal Herbalist*) in the PRC; and (c) the exploration of cooperation opportunities such as equity financing by utilising the Company’s platform.

INFORMATION ON ROYAL HERBALIST

So far as the Directors understands from Royal Herbalist, Royal Herbalist is a large scale medicine company which is engaged in the research, production and sale of Chinese medicine and the plantation and trading of Chinese medical herbs, and also provides Chinese medical services under the brand name of 樂家老藥鋪.

To the best of the Directors' knowledge, information and belief, and having made all reasonable enquires, Royal Herbalist and its ultimate beneficial owners are independent of, and not connected with, the Company and any of its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited).

REASONS AND BENEFITS FOR ENTERING INTO THE FRAMEWORK AGREEMENT

The Company entered into the Framework Agreement with the intention of leveraging on the Parties' respective strength, resources and expertise, which in turn could enhance the Group's competitiveness.

The Board wishes to emphasise that the implementation of the cooperation and transactions contemplated under the Framework Agreement (if any) are subject to the definitive agreement(s) to be entered into between the Parties, and such cooperation and transactions may not necessarily be implemented as contemplated or at all. Shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company.

By order of the Board
**Common Splendor International
Health Industry Group Limited**
Cheung Wai Kuen
Chairman

Hong Kong, 14 December 2016

As at the date of this announcement, the Board comprises Mr. Cheung Wai Kuen, Mr. Cheng Hau Yan and Mr. Ye Jiong Xian as executive Directors; Mr. Lin Jiang as non-executive Director; and Mr. Mai Yang Guang, Mr. Yau Chi Ming and Mr. Lam Chi Wing as independent non-executive Directors.

* *For identification purposes only*